BioLine RX

BLRX · TEL

$2.21+$0.2345 (+11.84%)TodayMarket closed · Oct 20, 6:52 PM ET

Prev close $1.98

BLRX analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Dec 8, 2025

Bull case

BioLine Rx Ltd is advancing its oncology-focused pipeline, notably with motixafortide (BL-8040), which has demonstrated promising results in combination therapies for treating metastatic pancreatic ductal adenocarcinoma (mPDAC), a notoriously challenging condition. The evidence of deep and potentially durable responses, alongside increased CD8+ T-cell infiltration in patients showing partial responses or stable disease, underscores the therapeutic potential of motixafortide. Additionally, BioLine Rx benefits from ongoing revenue generation through milestone payments from existing out-licensing agreements, enhancing its financial stability as it pursues further clinical developments.

Bear case

BioLine Rx Ltd faces significant risks that contribute to a negative outlook on its stock, primarily due to its reliance on the success of its clinical-stage therapeutic candidates, motixafortide and AGI-134. The potential for failed or inconclusive clinical trials poses a substantial threat to the company's ability to progress its drugs through the development pathway, which may hinder future growth and revenue generation. Additionally, the company's reliance on securing adequate funding to support its development efforts adds another layer of uncertainty, impacting its long-term financial stability and market position.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.